Identification of transcription factors associated with castration-resistance: Is the serum responsive factor a potential therapeutic target?

Prostate

Volumn 73, Issue 7, 2013, Pages 743-753

  Prencipe, Maria ^a   Madden, Stephen F ^b   O'Neill, Amanda ^a   O'Hurley, Gillian ^c   Culhane, Aedin ^d   O'Connor, Darran ^a   Klocker, Helmut ^e   Kay, Elaine W ^f   Gallagher, William M ^a,c   Watson, William R ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b DUBLIN CITY UNIVERSITY   (Ireland)

^c ONCOMARK LIMITED   (Ireland)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f BEAUMONT HOSPITAL   (Ireland)

Author keywords

advanced prostate cancer; serum response factor (SRF); transcription factors prediction analysis

Indexed keywords

CUT LIKE HOMEODOMAIN PROTEIN; HEAT SHOCK TRANSCRIPTION FACTOR 1; HOMEODOMAIN PROTEIN; INTERFERON REGULATORY FACTOR 4; PAIRED BOX GENE 5; PEPTIDES AND PROTEINS; POU CLASS 6 HOMEOBOX 1; PRE B CELL LEUKEMIA HOMEOBOX 1; RETINOID X RECEPTOR ALPHA; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 143;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN BINDING;

ANDROGENS; BLOTTING, WESTERN; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORCHIECTOMY; PROSTATE; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; SERUM RESPONSE FACTOR;

EID: 84876287828     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22618     Document Type: Article

References (43)

1. Pienta KJ, Bradley D,. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12 (6): 1665-1671.
2. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS,. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-4454.
3. Gill C, Dowling C, O'Neill AJ, Watson RW,. Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol Cancer 2009; 8: 39.
4. Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, Sella A, Daugaard G, Gil T, Graham J, Carpentier P, Calabro F, Collette L, Lacombe D,. EORTC Genitourinary Tract Cancer Group Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): An EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20 (7): 1264-1269.
5. Best CJM, Gillespie JW, Yi Y, Chandramouli GVR, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, González S, Velasco A, Linehan WM, Matusik RJ, Price DK, Figg WD, Emmert-Buck MR, Chuaqui RF,. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005; 11: 6823-6834.
6. Wei Q, Li M, Fu X, Tang R, Na Y, Jiang M, Li Y,. Global analysis of differentially expressed genes in androgen-independent prostrate cancer. Prostate Cancer Prostatic Dis 2007; 10: 167-174.
7. D'Antonio JM, Ma C, Monzon FA, Pflug BR,. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence. Prostate 2008; 68: 698-714.
8. Stoss O, Werther M, Zielinski D, Middel P, Jost N, Rüschoff J, Henkel T, Albers P,. Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis 2008; 11: 166-172.
9. Jeffery IB, Madden SF, McGettigan PA, Perriere G, Culhane AC, Higgins DG,. Integarting transcription factor binding site information with gene expression datasets. Bioinformatics 2007; 3: 298-305.
10. Dolédec S, Chessel D,. Co-inertia analysis: An alternative method for studying species-Environment relationships. Freshwater Biol 1994; 31: 277-294.
11. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H,. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumor progression in a new model system. Br J Cancer 1999; 81 (2): 242-251.
12. Dolédec S, Chessel D,. Rhythmes saisonniers et composantes stationelles en milieu aquatique I-Description d'un plan d'observations complet par projection de variables. Acta Oecologica Oecologica Generalis 1987; 8: 403-426.
13. Sun Q, Chen G, Streb JW, Long X, Yang Y, Stoeckert CJ Jr, Miano JM,. Defining the mammalian CArGome. Genome Res 2006; 16 (2): 197-207.
14. Heemers HV, Regan KM, Dehm SM, Tindall DJ,. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: Evidence for a role for serum response factor in prostate cancer. Cancer Res 2007; 67 (21): 10592-10599.
15. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ,. Prioritizing genes associated with prostate cancer development. BMC Cancer 2010; 10: 599.
16. Heemers HV, Schmidt LJ, Sun Z, Regan KM, Anderson SK, Duncan K, Wang D, Liu S, Ballman KV, Tindall DJ,. Identification of a clinically relevant androgen-dependent gene signature in prostate cancer. Cancer Res 2011; 71 (5): 1978-1988.
17. 388 enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling. Clin Cancer Res 2011; 17 (13): 4355-4366.
18. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP,. Exploration, normalization, and summaries of high-density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
19. Smyth GK,. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article 3.
20. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289-300.
21. Dray S, Chessel D, Thioulouse J,. Co-inertia analysis and the linking of ecological data tables. Ecology 2003; 84: 3078-3089.
22. Culhane AC, Perrière G, Considine EC, Cotter TG, Higgins DG,. Between-group analysis of microarray data. Bioinformatics 2002; 18: 1600-1608.
23. Culhane AC, Thioulouse J, Perrière G, Higgins DG,. MADE4: An R package for multivariate analysis of gene expression data. Bioinformatics 2005; 21: 2789-2790.
24. Breitling R, Armengaud P, Amtmann A, Herzyk P,. Rank products: A simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 2004; 573: 83-92.
25. Prencipe M, McGoldrick A, Perry AS, O'Grady A, Phelan S, McGrogan B, Fitzpatrick P, Watson JA, Furlong F, Brennan DJ, Lawler M, Kay E, McCann A,. MAD2 downregulation in hypoxia is independent of promoter hypermethylation. Cell Cycle 2010; 9 (14): 2856-2865.
26. O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, Rani S, O'Driscoll L, Fitzpatrick JM, Watson RW,. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer 2011; 10: 126.
27. Wingender E, Dietze P, Karas H, Knüppel R,. TRANSFAC: A database on transcription factors and their DNA binding sites. Nucleic Acids Res 1996; 24: 238-241.
28. Sandelin A,. JASPAR: An open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res 2004; 32: 91D-94D.
29. Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K, Lander ES, Kellis M,. Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature 2005; 434: 338-345.
30. Evelyn CR, Bell JL, Ryu JG, Wade SM, Kocab A, Harzdorf NL, Hollis Showalter HD, Neubig RR, Larsen SD,. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg Med Chem Lett 2010; 20 (2): 665-672.
31. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL,. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113 (6): 913-923.
32. Michl P, Ramjaun AR, Pardo OE, Warne PH, Wagner M, Poulsom R, D'Arrigo C, Ryder K, Menke A, Gress T, Downward J,. CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell 2005; 7 (6): 521-532.
33. Shaffer AL, Emre NC, Romesser PB, Staudt LM,. IRF4: Immunity. Malignancy! Therapy ? Clin Cancer Res 2009; 15 (9): 2954-2961.
34. Izumi H, Wakasugi T, Shimajiri S, Tanimoto A, Sasaguri Y, Kashiwagi E, Yasuniwa Y, Akiyama M, Han B, Wu Y, Uchiumi T, Arao T, Nishio K, Yamazaki R, Kohno K,. Role of ZNF143 in tumor growth through transcriptional regulation of DNA replication and cell-cycle-associated genes. Cancer Sci 2010; 101 (12): 2538-2545.
35. Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, Igarashi T, Niina I, Wakasugi T, Imaizumi T, Momii Y, Kuwano M, Kohno K,. Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 2005; 5 (1): 15-27.
36. O'Brien P, Morin P Jr, Ouellette RJ, Robichaud GA,. The Pax-5 gene: A pluripotent regulator of B-cell differentiation and cancer disease. Cancer Res 2011; 71 (24): 7345-7350.
37. O'Callaghan-Sunol C, Sherman MY,. Heat shock transcription factor (HSF1) plays a critical role in cell migration via maintaining MAP kinase signalling. Cell Cycle 2006; 5 (13): 1431-1437.
38. Butcher NJ, Minchin RF,. Arylamine N-acetyltransferase 1 gene regulation by androgens requires a conserved heat shock element for heat shock factor-1. Carcinogenesis 2010; 31 (5): 820-826.
39. Gombart AF, Luong QT, Koeffler HP,. Vitamin D compounds: Activity against microbes and cancer. Anticancer Res 2006; 26 (4A): 2531-2542.
40. Donkena KV, Young CY,. Vitamin D, sunlight and prostate cancer risk. Adv Prev Med 2011; 2011: 281863.
41. Kikugawa T, Kinugasa Y, Shiraishi K, Nanba D, Nakashiro K, Tanji N, Yokoyama M, Higashiyama S,. PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation. Prostate 2006; 66 (10): 1092-1099.
42. Alvarez A, Woolf PJ,. RegNetB: Predicting relevant regulator-gene relationships in localized prostate tumor samples. BMC Bioinformatics 2011; 12: 243.
43. Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H,. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 2004; 58 (3): 259-268.